All articles

2019 marks the 30th Anniversary of the ESMO Fellowship Programme, a programme that has helped young oncologists to enhance their careers like Giannis Mountzios, Henry Dunant Hospital Center, Athens, Greece, who had the opportunity to broaden his experience internationally.

How ESMO is transforming the challenges from the COVID-19 pandemic into opportunities to re-shape the future of the oncology community 

Exciting new data show that adjuvant targeted agent olaparib after chemotherapy can cut the risk of BRCA-mutated breast cancer returning or spreading in women 

At an ESMO Live Roundtable, a panel of experts discussed the benefits and risk of COVID-19 vaccination in patients with cancer, the practicalities of vaccinating those undergoing immunosuppressant treatment and the potential advantages and disadvantages of flexible dosing intervals.

With multiple new therapies available, Prof. Johan Vansteenkiste says the search is on for biomarkers to better match patients to treatments 

At ELCC 2021, Prof. Fiona Blackhall sees hope for improving patients’ poor prognoses on the horizon  

Despite alternative modes of administering anticancer medicines have reinforced the idea that at-home cancer care may be sometimes feasible as well as preferred by patients, there are concerns about costs of and accessibility to these new opportunities. 

New insights into breast cancer immunology and genomics support further segmentation of patient subgroups and treatment approaches, says Prof. Sherene Loi 

Although knowledge on pathogenic germline variants has improved over the years, researchers are hunting for new genetic causes of cancer to better identify families at higher risk to develop the disease 

As the complexity of the cancer landscape increases, miscommunication and misunderstanding emerge as major obstacles to patient self-determination

Expert says widely applicable predictive testing is needed to improve prevention, diagnosis and treatment

Faced with an explosion in the complexity of genomic, imaging and clinical data, AI is rapidly becoming an indispensable tool for oncologists.

Despite early promises, advances are needed in targeting tumour-specific epitopes, overcoming the tumour microenvironment, and automating CAR-T production, explains Prof. Ulrike Köhl 

Efficacy of targeted therapies has enabled unprecedented survival gains in the last few years, but Prof. Jean-Charles Soria believes overcoming drug resistance is likely to be a local battle fought in the tumour microenvironment 

Trastuzumab has transformed the prognosis for women with HER2+ breast cancer. On the occasion of the ESMO Breast Cancer Virtual Congress 2021, leading oncology experts recall with enthusiasm the pioneering work of researchers like José Baselga in this field and push for continuous research to investigate how to further improve the treatment of this cancer sub-type

While mature data from trials have demonstrated that periodic rounds of low-dose CT scan reduce lung-cancer related mortality, major issues are now implementation of screening on a large-scale and how to engage the target population 

Tumour evolution is one of the primary reasons for resistance to treatment and researchers are now learning how to use it to lead tumours down a dead end

Prof. Fabrice André sees the journal, which has become one of the most cited oncology publications, as an opportunity to help more doctors improve patient outcomes with new technologies.